{"id":"vevizye-eye-drops","safety":{"commonSideEffects":[{"rate":null,"effect":"Instillation site pain or discomfort"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5940488","moleculeType":null,"molecularWeight":"498.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vevicianine is a selective agonist of alpha-7 nicotinic acetylcholine receptors found on lacrimal gland tissue. By activating these receptors, the drug stimulates increased tear secretion and improves tear film stability, addressing the underlying pathophysiology of dry eye disease. This mechanism helps restore natural tear production in patients with aqueous tear deficiency.","oneSentence":"Vevizye is a topical eye drop formulation containing vevicianine, a small molecule that activates nicotinic acetylcholine receptors to improve tear production and reduce dry eye symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:15:11.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (aqueous tear deficiency)"}]},"trialDetails":[{"nctId":"NCT07463950","phase":"PHASE4","title":"A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2026-01-20","conditions":"Dry Eye Disease (DED)","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8827,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vevizye® Eye Drops","genericName":"Vevizye® Eye Drops","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vevizye is a topical eye drop formulation containing vevicianine, a small molecule that activates nicotinic acetylcholine receptors to improve tear production and reduce dry eye symptoms. Used for Dry eye disease (aqueous tear deficiency).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}